Pharmaceutical or food composition and applications thereof, and saccharide extraction method

The described method efficiently extracts isofloridoside from seaweed, addressing inefficiencies in existing processes by producing a sweet-tasting, functional composition for use as a natural sweetener and health supplement with blood sugar-lowering and oral bacteria-inhibiting properties.

JP2024159466APending Publication Date: 2024-11-08SAGA UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024004028
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-26
Filing Date
2024-01-15
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing methods for extracting isofloridoside from seaweed are time-consuming, inefficient, and require complex processes, leading to high manufacturing costs and poor suitability as a sweetener due to bitterness and unknown effects on oral bacterial flora.

Method used

A method involving shredding, drying, and soaking seaweed in water at controlled temperatures to extract isofloridoside efficiently, followed by crystallization to enhance purity, allowing for the production of a sweet-tasting, blood sugar-lowering, appetite-suppressing, and oral bacteria-inhibiting composition.

Benefits of technology

The method achieves high extraction rates of isofloridoside with improved sweetness and functional properties, suitable for use as a natural sweetener, blood sugar level regulator, appetite suppressant, and oral bacteria inhibitor, offering a cost-effective and environmentally friendly solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159466000001_ABST
    Figure 2024159466000001_ABST
Patent Text Reader

Abstract

To provide a pharmaceutical or food composition that can be produced at low costs and with high quality and applications thereof, and a saccharide extraction method.SOLUTION: A pharmaceutical or food composition contains isofloridoside or a derivative thereof as an active ingredient, which is a sweetness composition exhibiting sweetness.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical or food composition and its uses, as well as a sugar extraction method related thereto, and in particular to a low-cost and highly safe pharmaceutical or food composition and its uses, as well as a sugar extraction method. [Background technology]

[0002] In recent years, as health consciousness has grown, the demand for natural food additives, functional foods, and even pharmaceuticals made from naturally derived ingredients has increased.

[0003] As such a naturally occurring ingredient, isofloridoside, one of the floridosides contained in the seaweed Nori, has been verified to have an anti-metabolic syndrome effect of reducing visceral fat (see, for example, Non-Patent Document 1). This floridoside is the common name for galactosylglycerol. In addition, Nori also contains a large amount of porphyran, a sulfated viscous polysaccharide with extremely high water retention, as a naturally occurring ingredient.

[0004] On the other hand, there is some seaweed that has been processed into raw seaweed or dried seaweed, known as "discolored seaweed," which is hardly used due to its low quality as a product in terms of appearance, etc. For example, dried seaweed is graded according to the degree of discoloration, such as grades 4 and 5, and much of it is discarded as waste seaweed.

[0005] It is known that the above-mentioned isofloridoside can be extracted from this raw seaweed, known as "discolored seaweed" (see, for example, Non-Patent Document 1, above).

[0006] In addition, a method is known in which "discolored seaweed" is defined as seaweed with a protein content of 30% by weight or less, and floridosides are extracted from such seaweed using only water at 0 to 30°C as a solvent (see Patent Document 1).

[0007] In addition, a method is known in which "discolored seaweed" is defined as seaweed with a protein content of 30% by weight or less, and floridosides are extracted from such seaweed using only water at 0 to 30°C as a solvent (see Patent Document 1).

[0008] In addition, from the viewpoint of functional foods, floridoside, which is different from the above-mentioned isofloridoside, is produced by reacting galactose with glycerol in the presence of phosphoric acid, and is claimed to be non-cariogenic because it changes saliva to an acidic state. It has also been suggested that it can be used as a sweetener in foods (see Patent Document 2). [Prior art documents] [Patent documents]

[0009] [Patent Document 1] JP 2007-290971 A [Patent Document 2] JP 2011-057610 A [Non-patent literature]

[0010] [Non-Patent Document 1] https: / / www.affrc.maff.go.jp / docs / public_offering / agri_food2016 / 25055c.html Summary of the Invention [Problem to be solved by the invention]

[0011] However, the method described in Patent Document 1 requires a long period of time, 10 to 16 hours, and thus has the problem of low extraction productivity. In addition, since the porphyran extracted as a by-product has very high water retention, it becomes sol-like when water is added to dried seaweed powder, and in order to separate the water as the extraction solvent from the sol, complicated steps such as suction filtration and centrifugation are required, which increases the production cost.

[0012] In addition to the desired isofloridosides, red algae also contain isomeric floridosides that are produced due to differences in the position of the hydroxyl group at which galactose is bonded to glycerol. In order to increase the accuracy of separating these isomeric floridosides, complicated processes are required, which increases production costs.

[0013] Furthermore, from the perspective of functional foods, as described in Patent Document 2 above, the fact that floridoside only changes human saliva to an acidic state means that its effect on the normal oral flora in the oral cavity is unclear, and therefore there is little evidence that it is anti-cariogenic, and its effects are unknown.

[0014] In addition, floridoside is not very sweet, and has a bitter, unpleasant taste, making it difficult to use it as a functional food with a sweet taste. Since floridoside has such poor sweetness, it is not suitable for the purpose of sweetening not only functional foods but also other uses in general. For example, it is difficult to use it as a sweetener that is a food composition added to various foods, or as a sweetener that is a pharmaceutical composition contained in pharmaceuticals.

[0015] The present invention has been made to solve the above-mentioned problems, and aims to provide a low-cost and highly safe pharmaceutical or food composition, uses thereof, and a method for extracting sugars. [Means for solving the problem]

[0016] As a result of extensive research, the inventors have uncovered new functionality in isofloridoside, which is derived from seaweed, and have further discovered an efficient method for extracting the sugars therefrom, thereby completing the present invention.

[0017] Thus, according to the present invention, there is provided a pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, which is a sweetening composition that exhibits a sweetness. Also, there is provided a pharmaceutical or food additive containing the sweetening composition. Also, there is provided a pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, which is a composition for lowering blood glucose levels that lowers blood glucose levels. Also, there is provided a pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, which is a composition for suppressing appetite that suppresses appetite. Also, there is provided a pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, which is a pharmaceutical or oral resident bacterial growth suppressing composition that suppresses the growth of oral resident bacteria. There is provided a pharmaceutical, health food, functional food, nutritional supplement, supplement, health functional food, specified health food, nutritional functional food, or functional food that contains the pharmaceutical or food composition.

[0018] Also provided is a sugar extraction method for extracting sugars from red algae, the method comprising the steps of: a shredding process for crushing the red algae; a drying process for drying the shredded red algae into sheets; a soaking process for soaking the sheets of seaweed in a soaking solution; and an extraction process for extracting isofloridoside or a derivative thereof as the sugar from the soaking solution. [Brief description of the drawings]

[0019] [Figure 1] 1 shows a flowchart of a saccharide extraction method according to a first embodiment of the present invention. [Diagram 2] 1 shows a flowchart of a saccharide extraction method according to a first embodiment of the present invention. [Diagram 3] 1 shows a flowchart of a saccharide extraction method according to a first embodiment of the present invention. [Figure 4] 4 shows a flowchart of a saccharide extraction method according to a second embodiment of the present invention. [Diagram 5]1 shows a flowchart of a saccharide extraction method according to a third embodiment of the present invention. [Figure 6] The results of the isofloridoside content in dried seaweed in Example 1 of the present invention are shown below. [Figure 7] The results of the floridoside and isofloridoside contents in dried seaweed in Example 1 of the present invention are shown below. [Figure 8] 1 shows the results of an investigation into the extraction method in Example 1 of the present invention. [Figure 9] 1 shows the purification method and results of the saccharide extraction method according to Example 1 of the present invention. [Figure 10] 1 shows the results of ESI-TOF-MS analysis of isofloridoside extracted by the saccharide extraction method of Example 1 of the present invention. [Figure 11] 1 shows the results of gas chromatography (GLC) analysis of isofloridoside extracted by the saccharide extraction method of Example 1 of the present invention (a), and the results of EI-GC-MS analysis (b). [Figure 12] 1 shows the results of 1H-NMR analysis of isofloridoside extracted by the saccharide extraction method of Example 1 of the present invention. [Figure 13] 1 shows the results of 13C-NMR analysis of isofloridoside extracted by the saccharide extraction method of Example 1 of the present invention. [Figure 14] The results of the extraction time, temperature, and extraction rate of isofloridoside (IF) and floridoside (F) extracted using the saccharide extraction method of Example 1 of the present invention are shown. [Figure 15] 3 shows the evaluation results of the sweetness quality of isofloridoside extracted by the saccharide extraction method of Example 2 of the present invention. [Figure 16] 4 shows the results of the blood glucose lowering effect of isofloridoside extracted by the saccharide extraction method of Example 3 of the present invention. [Figure 17] This shows the results of intracellular Ca2+ increase mediated by activation of endogenous T1R2 / T1R3 in mouse small intestinal endocrine L cells (STC-1 cells) by isofloridoside extracted by the saccharide extraction method of Example 3 of the present invention. [Figure 18]1 shows the results of GLP-1 levels in the medium 1 hour after the addition of isofloridoside extracted by the saccharide extraction method of Example 3 of the present invention. [Figure 19] 1 shows the results of confirming the sweetness intensity of isofloridoside according to Example 4 of the present invention (results of a sensory test). [Figure 20] 1 shows the results of the appetite suppressing effect of isofloridoside according to Example 5 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] (First embodiment) The pharmaceutical or food composition according to this embodiment contains isofloridoside or its derivatives as an active ingredient. The derivative means a compound in which the isofloridoside skeleton is substituted to an extent that does not significantly change the structure. For example, a compound in which some of the hydrogen atoms constituting isofloridoside are substituted with methyl groups is exemplified.

[0021] "Food use" refers to various types of food, including functional foods.

[0022] The medicinal uses include, for example, the prevention and / or treatment of diseases related to obesity and / or the oral cavity, and the medicinal products can be used for such purposes as medicines, such as diabetes, metabolic syndrome, and dental caries.

[0023] This isofloridoside or a derivative thereof is preferably an isofloridoside represented by the following chemical formula: Isofloridoside is a compound in which galactose and glycerol are bonded in a one-to-one ratio, with the galactose being bonded to the hydroxyl groups on the first and third carbons of the glycerol's three carbons. In other words, there are two types of isofloridoside compounds that are isomers of each other (1-O-(α-D-galactopyranosyl)glycerol and 3-O-(α-D-galactopyranosyl)glycerol). The present inventors have been the first to demonstrate at the molecular level that isofloridoside acts on the human sweet taste receptor (see the Examples below).

[0024] [ka]

[0025] Furthermore, the present inventors have confirmed that isofloridoside acts on sweet taste receptors on small intestinal endocrine cells and promotes the secretion of incretin (GLP-1; glucagon-like peptide-1), a gastrointestinal hormone that lowers blood glucose levels (see the Examples below). This incretin (GLP-1) has attracted attention as a hormone that acts against obesity and diabetes.

[0026] In addition, it has been reported that isofloridoside reaches the large intestine without being digested and absorbed in the small intestine, making it difficult for it to become an energy source for the body. Therefore, it is a zero-calorie molecule that is not absorbed in the small intestine to be used as energy. In addition, the present inventor has discovered that isofloridoside has the effect of suppressing the proliferation of normal oral bacteria (see the Examples below).

[0027] For these reasons, the pharmaceutical or food composition of this embodiment uses isofloridoside or a derivative thereof, and in particular isofloridoside or a derivative thereof, as an active ingredient, and thereby exhibits various functions such as a sweetening composition that exhibits a sweetness that can be used as a naturally derived, non-caloric sweetener, a blood glucose lowering composition that lowers blood glucose levels, an appetite suppressant composition that suppresses appetite, and a composition for inhibiting the proliferation of oral resident bacteria that suppresses the proliferation of oral resident bacteria.

[0028] In other words, when the pharmaceutical or food composition according to this embodiment is used as a sweetening composition that exhibits sweetness, it is not only expected to be used as a food additive as a non-caloric functional natural sweetener, but also can be used as a natural sweetener for diabetic patients. In addition, from the aspect of a pharmaceutical composition, it can be used as a non-caloric sweetener contained in medicines. As a result, for example, as a natural sweetener that is a food additive contained in medicines for diabetic patients, it can be used to constitute medicines that are safe and easy to take without worrying about sugar intake.

[0029] Conventional artificial sweeteners include low-calorie artificial sweeteners such as acesulfame K and aspartame, which are widely used in foods and in the management of type 2 diabetes (Li et al., 2011). However, there are concerns that such artificial sweeteners may stimulate fat production and cause addiction (Simon et al., 2013). Therefore, there is a strong demand for the development of new natural sweeteners with improved safety. The food composition according to this embodiment meets such needs as a sweetening composition that exhibits a sweetness derived from natural sources.

[0030] In addition, when the pharmaceutical or food composition according to the present embodiment is used as a blood glucose level lowering composition that lowers blood glucose levels, it can be used as a functional food, health food, or supplement as a natural non-calorie blood glucose level lowering food from the aspect of a food composition. Also, in the aspect of a pharmaceutical composition, it can be used as a blood glucose level lowering agent, for example, a medicine for diabetes patients or for preventing diabetes.

[0031] In addition, when the pharmaceutical or food composition according to the present embodiment is used as an appetite suppressant composition that suppresses appetite, it can be expected to be used as a natural, non-calorie appetite suppressant food, for example, as a health food or supplement for preventing overeating or for weight loss dieting, from the aspect of a food composition. Also, in terms of a pharmaceutical composition, it can be used as an appetite suppressant, which is a medicine for patients suffering from metabolic syndrome, including obesity, or for preventing metabolic syndrome.

[0032] In addition, when the pharmaceutical or food composition according to the present embodiment is used as a composition for inhibiting the proliferation of oral resident bacteria, it is expected that the composition can be used as a natural, non-caloric food for inhibiting the proliferation of oral resident bacteria, for example, as a health food or supplement for preventing dental caries. In addition, in terms of the pharmaceutical composition, it can be used as an oral care agent, an oral environment improving agent, or an agent for preventing dental caries, which is a medicine for improving the oral environment.

[0033] For these reasons, the pharmaceutical or food composition of this embodiment can be used in a wide range of applications, for example, as a pharmaceutical, health food, functional food, nutritional supplement, supplement, health functional food, food for specified health uses, nutritional functional food, or food with functional claims.

[0034] The method for producing isofloridoside or its derivatives, which are the active ingredients of the pharmaceutical or food composition according to the present embodiment and exhibit the excellent functions discovered by the present inventors, is not particularly limited. That is, the method for producing isofloridoside or its derivatives may be chemically synthesized or may utilize an extract derived from a natural product, and is not particularly limited.

[0035] Here, isofloridoside is contained in red algae such as Porphyra yezoensis (Neopyropia yezoensis) (Colin & Gueguen, 1930) (H. Noda, H. Abo, & Horiguchi, 1981), and is involved in osmotic adjustment, which stores the energy obtained through photosynthesis in red algae.

[0036] Isofloridoside is found in large quantities in red algae, particularly in Porphyra yezoensis, the raw material for seaweed, and its content in seaweed varies depending on the growing environment and growth of the seaweed. Also, the content of isofloridoside is particularly high in so-called discolored seaweed, and in some cases it accounts for more than 10% of the weight of the dried seaweed (see the examples below).

[0037] From this point of view, the active ingredient of the pharmaceutical or food composition according to this embodiment is not particularly limited as long as it is an extract of red algae, but for example, an extract of Nori sheet (slab-shaped Nori) can be used, and among these, an extract of discolored Nori is particularly preferable. In this embodiment, by using discolored Nori among the extracts of Nori sheet (slab-shaped Nori) as a raw material, isofloridoside can be efficiently extracted, and discolored Nori, most of which is discarded, can be effectively utilized, reducing waste to the environment, and it can be said to be an environmentally friendly technology.

[0038] (Manufacturing method) Isofloridoside or its derivatives, which are the active ingredients of the pharmaceutical or food composition of this embodiment, can be extracted from the above-mentioned red algae (Neopyropia yezoensis) as a raw material by the saccharide extraction method of this embodiment, although there is no particular limitation.

[0039] The red algae used as the raw material are not particularly limited, but those belonging to the genus Neopyropia are preferred.

[0040] First, as shown in Fig. 1, the red algae Neopyropia yezoensis is washed with seawater or fresh water, then shredded into a minced meat and pulverized (S1: shredding step). More preferably, in the shredding step (S1), the red algae is shredded into pieces of 2.5 mm to 5.0 mm and pulverized.

[0041] Next, the shredded red algae is rolled up on a seaweed mat and dried into a sheet (S2: drying step). This drying method is not particularly limited, but can be, for example, air drying at a temperature of 40 to 80°C for 2 to 3 hours until the moisture content is about 10%.

[0042] In other words, the process up to this point is the same as the conventional manufacturing method for sheet seaweed (seaweed sheets). Therefore, there is an advantage that existing equipment for manufacturing sheet seaweed (seaweed sheets) can be used as is.

[0043] The sheet of seaweed is immersed in an immersion solution (S3: immersion step). The immersion solution is not particularly limited, but it is preferable to use water in terms of availability, cost, and safety. For example, the immersion can be performed by placing dried seaweed (dried sheet of seaweed) on a net-like structure and immersing it in water.

[0044] Furthermore, after a certain period of immersion, the net-like structure is removed from the water and left to stand for a while, which allows the water, the extraction solvent, that clings to the nori sheets to be removed efficiently and easily. By immersing multiple sheets of nori sheets in water in the same way, isofloridoside can be extracted in the same way.

[0045] In this manner, isofloridoside or a derivative thereof is extracted as the saccharide from the soaking solution (S4: extraction step). More preferably, isofloridoside or a derivative thereof is extracted at an extraction temperature of 1 to 10°C and / or for an extraction time of 1 to 3 hours. For example, the extraction temperature can be 1 to 10°C and the extraction time can be 1 to 3 hours. When multiple sheets of nori are stacked for extraction, the extraction time required will be longer than when a single sheet of nori is used.

[0046] In this way, the seaweed to be immersed in the soaking solution is different from the conventional method of using raw seaweed, and in this embodiment, the dried seaweed is used in a sheet form. In other words, the dried seaweed is immersed in the soaking solution without being crushed.

[0047] It has been confirmed that, using this method, the extraction rate of isofloridoside exceeds 80% when soaked in water at 5°C for 3 hours (see the Examples below). In addition, when the same extraction was performed at 25°C, the extraction rate of isofloridoside was about the same, and even when three sheets of dried seaweed were extracted, the extraction rate of isofloridoside exceeded 70% when soaked in water at 5°C for 3 hours.

[0048] Thus, in this embodiment, the immersion time in the immersion solution does not require 10 hours or more as in the prior art of Patent Document 1, and isofloridoside or its derivatives can be efficiently extracted in an extremely short time and with high efficiency.

[0049] The mechanism behind this excellent effect has not yet been elucidated in detail, but as mentioned above, the seaweed has already been shredded in the process of processing it into sheets, particularly in the shredding step (S1), and soaking it without further powdering is thought to promote the extraction of isofloridoside or its derivatives.

[0050] More preferably, as shown in Fig. 2, after the drying step (S2), discolored sheets of nori are selected from the dried sheets of nori produced by the drying step (S21: selection step). For this selection, for example, the brightness and protein content of the sheets of nori can be measured and the discolored sheets of nori can be selected based on a threshold value that serves as a judgment criterion. In addition, for example, low-quality discolored nori that was not subject to market trading (bidding) can also be used.

[0051] By selecting the discolored seaweed, it is possible to extract isofloridoside at a higher content. Thereafter, the selected seaweed sheets are immersed in a soaking solution (above S3: soaking step) in the same manner as above, and isofloridoside or its derivatives are extracted as sugars from the soaking solution (above S4: extraction step).

[0052] Furthermore, as shown in FIG. 3, isofloridoside or a derivative thereof extracted in the extraction step can be crystallized (S5: purification step).

[0053] The crystallization process is not particularly limited, but for example, crystals can be precipitated by adding absolute ethanol, heating to dissolve, and then cooling to 1° C. to 5° C. It is also possible to add ethanol and leave at 4° C. for one week to generate isofloridoside crystals.

[0054] Since the extract contains the same amount of floridoside as the other components, the purity of isofloridoside can be further increased by performing crystallization in the final stage of purification.

[0055] Second embodiment The saccharide extraction method according to the second embodiment includes the shredding step, the drying step, the sorting step, the soaking step, and the extraction step, similar to the first embodiment described above, and further includes a re-extraction step (S6) of extracting porphyran as the saccharide from the extraction residue obtained by the extraction step, as shown in FIG. 4.

[0056] Since the polysaccharide porphyran hardly dissolves in cold water, most of the porphyran remains in the extraction residue in cold water at 5°C. In this re-extraction step (S6), this is used as the raw material for porphyran extraction. The extraction residue can be used to extract porphyran, a sulfated viscous polysaccharide specific to red algae such as laver.

[0057] (Third embodiment) The saccharide extraction method of the third embodiment includes the shredding process, the drying process, the sorting process, the soaking process, the extraction process, and the re-extraction process, similar to the second embodiment described above, and further includes a control process (S7) for controlling the amount of porphyran extracted by the re-extraction process and the amount of isofloridoside or its derivative extracted by the extraction process by temperature, as shown in Figure 5.

[0058] By this control step (S7), for example, the temperature can be raised to a higher temperature (near 90°C) to increase the amount of Porphyran selectively extracted, or the temperature can be lowered to a lower temperature (near 5°C to 20°C) to increase the amount of isofloridoside or its derivatives selectively extracted.

[0059] This is based on the extraction temperature characteristics of porphyran and isofloridoside. In other words, porphyran is more easily extracted when extracted at high temperatures (around 90°C). Also, isofloridoside has the property of being easily extracted at both low and high temperatures.

[0060] For this reason, this control process selectively extracts isofloridoside at low temperatures (around 5°C to 20°C) and then porphyran is selectively extracted at high temperatures (around 90°C). In this way, the desired compound can be freely, easily and efficiently obtained by controlling the temperature.

[0061] The present invention will be described in more detail below by showing examples, but the present invention is not limited to the following examples.

[0062] Example 1 In the following, dried seaweed (dried sheet-shaped seaweed) (provided by Ariake Fisheries Cooperative Association, Saga Prefecture) was used as the red algae.

[0063] (1) Confirmation of the content of isofloridoside or its derivatives in dried seaweed The content of isofloridoside or its derivatives in the dried seaweed was confirmed. The results are shown in Figure 6. The isofloridoside content of the discolored seaweed was 242.8 (mg / g-dried seaweed) in discolored seaweed A (harvested in January 2019) and 94.6 (mg / g-dried seaweed) in discolored seaweed B (harvested in January 2021), both of which showed high values.

[0064] The results of measuring the content of floridoside (F) and isofloridoside (IF) in different grades of dried seaweed are shown in the following table and Figure 7. Among the dried seaweed tested, grade 7 and grades A3 to A5 are considered to be sufficiently low grades in the industry, and in terms of appearance, they are in the category of so-called discolored seaweed. [Table 1]

[0065] The results confirmed that all grades of dried seaweed contained isofloridoside (IF). Of these, it was confirmed that the lower the quality of seaweed (discolored seaweed), indicated by grades 7 and A3 to A5, the higher the isofloridoside content. In seaweed with a particularly high content, the isofloridoside content reached up to 20% of the dry weight.

[0066] (2) Consideration of extraction method We also investigated an extraction method using dried seaweed, as shown in Figure 8. The upper photograph in Figure 8 shows the state after 24 hours of soaking at 25°C. The lower photograph in Figure 8 shows the state after 24 hours of soaking at 5°C. In the low-temperature water, the dried seaweed did not fall apart and its shape remained stable. This made it very easy to drain the water afterwards.

[0067] (3) Extraction of isofloridoside from red algae According to the first embodiment, isofloridoside was extracted from red algae. That is, dried seaweed was washed with seawater or fresh water, then shredded into mince and crushed. Next, the shredded dried seaweed was rolled up on a seaweed mat and air-dried at a temperature of 40 to 80°C for 2 to 3 hours to a moisture content of about 10%, and dried into a sheet.

[0068] In other words, the process up to this point is the same as the conventional manufacturing method for sheet seaweed (seaweed sheets). Therefore, existing equipment for manufacturing sheet seaweed (seaweed sheets) can be used as is.

[0069] Among the dried sheets of seaweed produced by the drying process, sheets of seaweed that had lost their color were selected (S21: selection process). The dried seaweed was placed on a net-like structure and immersed in water (S3: immersion process).

[0070] Furthermore, after soaking the seaweed sheets at an extraction temperature of 1 to 10°C for 1 to 3 hours, the net-like structure was removed from the water and left to stand for a while, which allowed for efficient and simple removal of the water, the extraction solvent, that had clung to the seaweed sheets. Isofloridoside was extracted in the same manner (S4: extraction step).

[0071] As shown in Figure 9, an extract with a purity of 51.5% was obtained from 93.6 g of discolored seaweed (equivalent to 29 dried seaweed sheets), which was then ion-exchanged to obtain an extract with a purity of 83.5%, and then ultrafiltration to obtain an extract with a purity of 96.7%. After that, anhydrous ethanol was added, the mixture was heated to dissolve, and then cooled to 4°C to precipitate crystals, yielding 9.6 g of crystals. The crystal analysis shown below confirmed that the crystals had been refined to an isofloridoside content of 96.7% (flouridoside content of 3.3%).

[0072] Figure 10 shows the ESI-TOF-MS analysis results of the crystals extracted by the above sugar extraction method. The results show that the crystals have a molecular weight of 254.10 and a molecular formula of CH 18The crystals were identified as O8. The results of gas chromatography (GLC) analysis of 20 μg of the crystals extracted by the above sugar extraction method are shown in Figure 11(a). The internal standard was D-mannitol. This confirmed that the crystals contained isofloridoside:flouridoside in a ratio of 96.7:3.3.

[0073] Figure 11(b) shows the EI-GC-MS analysis results for 20 μg of the crystals extracted by the above sugar extraction method. The results confirmed that the spectrum of the crystals was indeed consistent with that of floridosides.

[0074] Figure 12 shows the crystals extracted using the above sugar extraction method. 1 The results of H-NMR analysis are shown in Fig. 13. 13 The results of C-NMR analysis are shown below. L-isofluoridoside and D-isofluoridoside are two compounds that are isomers of isofloridoside, 1-O-(α-D-galactopyranosyl)-glycerol and 3-O-(α-D-galactopyranosyl)glycerol, respectively. From the results obtained, it was confirmed that the ratio of L-isofluoridoside to D-isofluoridoside was 75.4:24.6. It was also confirmed that the ratio of isofloridoside to isofloridoside was 97.6:2.4.

[0075] Figure 14 shows the relationship between extraction time, temperature, and extraction rate of isofloridoside (IF) and floridoside (F) that can be extracted from dried seaweed. It was confirmed that the extraction rate at an extraction temperature of 25°C was significantly higher, especially for short extraction times of less than one hour. Even at an extraction temperature of 5°C, more than 80% was extracted after two hours of extraction, and the extraction rate remained almost constant thereafter. Even when extracting three sheets of dried seaweed stacked together, the extraction rate of isofloridoside exceeded 70% at 5°C for three hours.

[0076] (4) Sweetness quality evaluation The sweetness quality of the seaweed extract (isoflouridoside) aqueous solution was evaluated using a sucrose aqueous solution as the standard. A panel of six tasters, using 2 ml of sample, compared 3% sucrose aqueous solution with 3.0%, 6.0%, and 9.0% seaweed extract (isoflouridoside) aqueous solutions under blind conditions, and selected the one with the stronger sweetness. The results of the sweetness quality evaluation are shown in Figure 15.

[0077] As shown in the results in Figure 15, the sweetness of isofloridoside extracted from seaweed was evaluated to be characterized by a strong, refreshing sweetness, a weak aftertaste, and a long-lasting taste that did not linger in the mouth.

[0078] (5) Calculation of sweetness The seaweed extract obtained above was 6.0% isofloridoside (equivalent to 3% sucrose), and the isofloridoside concentration was calculated to be 5.2%, based on the isofloridoside content in the refined product used in this experiment: 86.2%. As a result, the sweetness of isofloridoside was calculated to be 0.58 (3.0 / 5.2 ≒ 0.58), relative to the sweetness of sucrose, which is set to 1 as an index of the sweetness of sweeteners. This is about the same sweetness as the existing sweetener xylitol.

[0079] Example 2 In order to confirm the sweetness of isofloridoside derived from red algae, we examined its sweet taste receptor T1R2 / T1R3 activation activity.

[0080] Dried seaweed (provided by the Ariake Fisheries Cooperative Association, Saga Prefecture) was used as the red algae. Dried sheet-shaped seaweed was crushed in a mixture of MeOH / CHCl3 / H2O (12 / 5 / 3, v / v / v) and then crushed under 5000 × g (gravitational acceleration: 1 g [gravity] = 9.807 [m / s 2 The supernatant was collected by centrifugation for 5 minutes at 37°C for 10 min at 100°C for 2 min. The supernatant was concentrated, and the residue was redissolved in distilled water and fractionated by passing through a column of a cationic resin (AGR50-X8 hydrogen type, BioRad) and an anionic resin (AGR1-X8 hydroxide type, BioRad) to remove ionic molecules.

[0081] The flow-through fraction was dried and dissolved in distilled water. Ethanol was added to a final concentration of about 89%. The solution was left to stand at 4° C. for 2 weeks to induce crystallization of isofloridoside. The isolated crystals were identified as isofloridoside by nuclear magnetic resonance (NMR) analysis as in Example 1 above, and their purity was estimated to be 95% or higher using GC-MS.

[0082] Humans sense sweetness through a heterodimeric receptor complex consisting of taste receptor type 1 member 2 (T1R2) and taste receptor type 1 member 3 (T1R3) present in taste bud cells. The receptor reacts only to sweet substances after forming a T1R2 / T1R3 heterodimer. When the heterodimer binds to a sweet substance, it becomes activated and a sweet taste signal is transmitted to the brain. Both T1R2 and T1R3 receptors are known to play important roles in the recognition and binding of various sweet substances.

[0083] Taste bud cells express both T1R2 / T1R3 and a unique heterotrimeric G protein, gustducin. The alpha subunit of gustducin (Gαgust) is required for T1R2 / T1R3 signaling.

[0084] (1) Western blotting T1R2, T1R3, and gustducin expression plasmids were transfected into HEK293T cells using polyethyleneimine (PEI). After 24 hours, the medium was changed to serum-free DMEM. After an additional 6 hours of culture, the cells were treated with 10 mM isofloridoside, acesulfame K (Ace K), or HHBS (Hank's buffer containing 20 mM HEPES) for 10 minutes. The cells were harvested and lysed using a buffer consisting of 50 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM EDTA, PhosSTOP® (Roche Diagnostics) and Complete® EDTA-free (Roche Diagnostics). Proteins were separated by polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting was performed.

[0085] Chemiluminescence was monitored using a chemiluminescence imaging device (LuminoGraph I, ATTO Corporation), and the signal was quantified using image analysis software (CS Analyzer, ATTO Corporation). The primary antibodies used were phosphor-p44 / 42 MAP kinase antibody and p44 / 42 MAP kinase antibody (Cell Signaling Technology). The secondary antibodies used were anti-mouse F(ab')-HRP and anti-rabbit F(ab')-HRP (Medical and Biological Laboratories, Inc.).

[0086] (2) Intracellular Ca 2+ Concentration measurement To examine whether isofloridoside acts on T1R2 / T1R3, we measured intracellular Ca in cultured cells. 2+ The change was measured.

[0087] Intracellular Ca 2+The concentration was measured using the calcium indicator Calbryte® 520 am (AAT Bioquest). Fluorescence was measured using a microplate reader Infinite F200 PRO (TECAN Group) at an excitation wavelength of 488 nm and an emission wavelength of 510 nm. Acesulfame K (Ace K) (10 mM), isofloridoside (10 mM), HHBS (Hank's buffer solution containing 20 mM HEPES), or lactisole (4 mM) were added using an injector attached to the device.

[0088] As shown in Figure 16(A), after the addition of isofloridoside, intracellular Ca 2+ A rapid increase in Ca was observed (arrow in the figure). However, in the cells transfected with the control plasmid, 2+ Thus, as shown in Figure 16 (A) and (B), isofloridoside increased intracellular Ca in a T1R2 / T1R3-dependent manner. 2+ It was confirmed that this increased

[0089] As shown in Figure 16(B), a known artificial sweetener, acesulfame K (Ace K), like isofloridoside, also increased intracellular Ca in a T1R2 / T1R3-dependent manner. 2+ The concentration of Ace K was increased. Ace K is an artificial sweetener that is 200 times sweeter than sucrose and is known to be a strong T1R2 / T1R3 activator. As shown in Figure 16(C), isofloridoside increased the phosphorylation of Erk, a downstream component of the T1R2 / T1R3 signaling pathway that is phosphorylated upon receptor activation.

[0090] The sweetness of isofloridoside has not been elucidated until now. However, the results of this study indicate that isofloridoside increases intracellular Ca in T1R2 / T1R3 expressing HEK293T cells. 2+These results confirmed that isofloridoside interacts with T1R2 / T1R3 to transmit sweetness, indicating that isofloridoside acts as a novel sweetener.

[0091] Example 3 (Confirmation of blood sugar lowering effect) In order to confirm the blood glucose level lowering effect of the red algae-derived isofloridoside obtained in Example 2 above, the secretion-promoting effect of incretin (GLP-1), a gastrointestinal hormone that has a blood glucose level lowering effect, was confirmed.

[0092] (1)Cell culture The HEK293T cell line (obtained from Riken BRC) was cultured in Dulbecco's modified Eagle's medium (D-MEM, Sigma Aldrich) supplemented with 10% fetal bovine serum, and the mouse small intestine endocrine L cell (STC-1 cell) (CRL-3254) cell line (obtained from the American Type Culture Collection (ATCC)) was cultured in D-MEM (Sigma Aldrich) supplemented with 5% fetal bovine serum and 5% horse serum.

[0093] (2) Enzyme-linked immunosorbent assay for incretin (GLP-1) Mouse small intestinal endocrine L cells (STC-1 cells) were cultured in 24-well plates. The medium was changed to glucose-free DMEM (Fujifilm Wako Pure Chemical Industries, Ltd.) and supplemented with 1 mM sodium pyruvate and 4 mM L-glutamine for 6 h. Acesulfame K (Ace K) (10 mM), isofloridoside (10 mM), α-linolenic acid (ALA, 25 μM) or HHBS was added, and the medium was collected 60 min later. The amount of incretin (GLP-1) in the medium was measured using an incretin (GLP-1) ELISA kit (Fujifilm Wako Pure Chemical Industries, Ltd.).

[0094] Isofloridoside increases intracellular Ca through activation of endogenous T1R2 / T1R3. 2+It induces an increase in the levels of insulin and promotes the secretion of incretin (GLP-1) in mouse small intestinal endocrine L cells (STC-1 cells). In recent years, it has become clear that sweet taste receptors are expressed in various organs throughout the body and play important roles.

[0095] In the digestive tract, it acts as a nutritional sensor and is known to play an important role in the secretion of incretin (GLP-1), a group of metabolic hormones. Incretin (GLP-1) has various functions such as suppressing appetite and promoting insulin secretion, and has anti-obesity and anti-diabetic effects. In other words, incretin (GLP-1) has the function of delaying the discharge of food into the intestine and suppressing postprandial hyperglycemia in the stomach. In addition, in the pancreas, it has the function of promoting insulin secretion, suppressing glucagon secretion, and lowering blood glucose levels. In addition, in the brain and central nervous system, it has the function of suppressing appetite. Inhibitors of the incretin (GLP-1) decomposition enzyme DPP4 are sold as treatments for type 2 diabetes.

[0096] The physiological function of isofloridoside in the digestive tract was confirmed using mouse small intestinal endocrine L cells (STC-1 cells) that can secrete incretin (GLP-1). That is, isofloridoside extracted by the above sugar extraction method increased intracellular Ca2+ levels via activation of endogenous T1R2 / T1R3 in mouse small intestinal endocrine L cells (STC-1 cells). 2+ The results of the increase are shown in FIG.

[0097] Figure 17(A) shows the results of examining the expression levels of T1R2 and T1R3 in mouse small intestinal endocrine L cells (STC-1 cells) by qPCR (*p < 0.05). As shown in Figure 17(A), a significant difference was observed in the expression levels of T1R2 and T1R3, but it was confirmed that both T1R2 and T1R3 were expressed at sufficient levels in mouse small intestinal endocrine L cells (STC-1 cells).

[0098] Ca in mouse intestinal endocrine L cells (STC-1 cells) 2+Using the probe calcium indicator Calbryte® 520-AM (Cosmo Bio Co., Ltd.), intracellular Ca 2+ The results of measuring the change in are shown in Figure 17(B). The black arrows in Figure 17(B) indicate the time points when isofloridoside (IF) and acesulfame K (Ace K) were added, and the white arrows in Figure 17(B) indicate the time points when lactisol was added.

[0099] Lactisol is a naturally occurring carboxylic acid that is known to inhibit sweet and umami tastes by binding to the transmembrane domain (TMD) of taste receptor type 1 member 3 (T1R3).

[0100] As shown in Figure 17(B), the addition of both isofloridoside and Ace K increased intracellular Ca 2+ A rapid increase in concentration was confirmed (black arrow in the figure).

[0101] The average fluorescence intensity was calculated 20 seconds after the addition of Ace K, isofloridoside, and lactisol, and the results are shown in Figure 17(C) and (D). Error bars represent SD from four independent experiments (**p < 0.01). All statistical analyses were performed using Student's t-test.

[0102] Addition of lactisol to the cells increased intracellular Ca as shown in Figure 17(B) (white arrow), (C), and (D). 2+ These results suggest that isofloridoside and Ace K increase intracellular Ca concentration by interacting with T1R2 / T1R3, which are endogenously expressed in STC-1 cells. 2+ It was clearly confirmed that it increased the levels.

[0103] One hour after adding isofloridoside, Ace K, or α-linolenic acid (ALA) to STC-1 cells, the medium was collected and the amount of GLP-1 was quantified using ELISA. The results of GLP-1 levels in the medium one hour after adding the extracted isofloridoside are shown in Figure 18. Error bars represent SD from three independent experiments (*p < 0.05). Statistical analysis was performed using Student's t-test.

[0104] The results confirmed that the incretin (GLP-1) level in the culture medium was significantly increased. In other words, it was confirmed that isofloridoside promotes the secretion of incretin (GLP-1) from STC-1 cells. Free fatty acid receptor 4 (FFAR4) is known to be the main receptor involved in GLP-1 secretion in the gastrointestinal tract. Isofloridoside acts on T1R2 / T1R3 and induced incretin (GLP-1) secretion with a strength equivalent to that of FFAR4 activation by ALA.

[0105] Example 4 (Confirming sweetness intensity) A blind taste test was conducted on five subjects to confirm the sweetness of the red algae-derived isofloridoside obtained in Example 2 as a sweetener or sweetener. Sucrose, glycerin, and floridoside (Massa extract) were used as comparative examples. Each was tested at a 500 mM solution concentration. The results are shown in Figure 19.

[0106] As shown in Figure 19, the results showed that the sweetness of isofloridoside as a sweetener or sweetener is close to that of sucrose, which is generally considered to be strong in sweetness. Specifically, the subjects' responses included the view that the sweetness was stronger and stronger than that of glycerin, that it was a sweetness similar to that of sweeteners they had eaten regularly, and that even at a concentration of 10 mM, it was felt to be sufficiently sweet.

[0107] In addition, the results showed that the sweetness of floridoside as a sweetener or sweetener is even weaker than that of glycerin, which is generally considered to have a low sweetness. Specifically, the subjects' responses included the following opinions: it had a strange taste that was different from sweetness, they felt a slight sweetness that they did not like, and they did not feel any sweetness at a concentration of 10 mM.

[0108] This confirmed that the sweetness of isofloridoside is sufficiently strong to be practical as a sweetener or sweetening agent, whereas floridoside is not practical to be used as a sweetener or sweetening agent.

[0109] Example 5 (Confirmation of appetite suppressant effect) In order to confirm the appetite suppressant effect of the red algae-derived isofloridoside obtained in Example 2 above, food intake was confirmed after administration of isofloridoside to obese mice, using 0.9% saline as a comparison example.

[0110] First, mice (C57BL / 6J, CLEA Japan, Inc.) were introduced at 4 weeks of age and fed a high-fat diet (High Fat Diet32 (HFD32) for mice and rats, CLEA Japan, Inc.) for 10 weeks (70 days) to create obese mice (14 weeks of age, 36.2 g).

[0111] Next, after fasting for 3 hours, the obese mice were forced to receive oral administration under the following conditions. Isofloridoside group: 20% isofloridoside aqueous solution (2g / 10ml) Control group: 0.9% saline Dosage: 10 ml / kg of body weight

[0112] Thereafter, food intake was measured 16 hours after the administration.

[0113] The results of measuring food intake are shown in Figure 20. The results confirmed that the average food intake (kcal) in the isofloridoside group was reduced by 54%, from 13.3 kcal to 6.1 kcal, compared to the control group.

[0114] These results confirmed that isofloridoside significantly suppressed the appetite of mice (reduced by 46%) (p < 0.0003).

[0115] Example 6 (Confirmation of the effect of inhibiting the proliferation of normal oral bacteria) Concerning the normal oral bacteria, the mutans group is classified into seven species, of which Streptococcus mutans and Streptococcus sobrinus are present in the human oral cavity, and both are involved in dental caries. Streptococcus mutans activates the caries process by using a group of enzymes contained within the bacteria. Using sucrose as a substrate, it produces glucan by glucosyltransferase. This glucan allows the bacteria to adhere strongly to the smooth surfaces of teeth, forming plaque.

[0116] The red algae-derived isofloridoside obtained in Example 2 was examined for its utility as a carbon source (growth evaluation using minimal medium) in order to confirm its inhibitory effect on the proliferation of oral flora. The cells were cultured for 2 days at 37°C and 5% CO2 concentration using SDM raw agar medium. The results are shown below. <Legend> 〇: Growth present (visually turbid) x: No growth (no visible turbidity) nt: Not tested

[0117] [Table 2]

[0118] [Table 3]

[0119] The results confirmed that oral Streptococcus bacteria, including the caries-causing bacteria S.mutans, cannot use isofloridoside as a carbon source and that it has no bactericidal effect. These results indicate that isofloridoside has a favorable effect on the oral flora, including its anti-cariogenic properties. This means that isofloridoside creates an effective environment for the oral flora in terms of protecting the good bacteria in the oral cavity, and plays a very important role in the oral environment.

Claims

1. A pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, The composition is characterized by having a sweet taste. Pharmaceutical or food compositions.

2. A pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, The composition is characterized by lowering blood sugar levels. Pharmaceutical or food compositions.

3. A pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, It is characterized as an appetite suppressant composition that suppresses appetite. Pharmaceutical or food compositions.

4. A pharmaceutical or food composition containing isofloridoside or a derivative thereof as an active ingredient, The composition is characterized in that it is a composition for inhibiting the proliferation of oral resident bacteria, which inhibits the proliferation of oral resident bacteria. Pharmaceutical or food compositions.

5. The pharmaceutical or food composition according to any one of claims 1 to 4, The active ingredient is an extract of red algae. Pharmaceutical or food compositions.

6. The pharmaceutical or food composition according to claim 5, The red algae is characterized in that it belongs to the genus Neopyropia. Pharmaceutical or food compositions.

7. The pharmaceutical or food composition according to claim 6, The red algae is characterized in that it is a plate-shaped seaweed. Pharmaceutical or food compositions.

8. The pharmaceutical or food composition according to claim 7, The sheet seaweed is characterized in that the sheet seaweed is discolored. Pharmaceutical or food compositions.

9. A sweetener composition according to claim 1, Pharmaceutical or food additives.

10. A pharmaceutical or food composition comprising the pharmaceutical or food composition according to any one of claims 1 to 4. Pharmaceuticals, health foods, functional foods, dietary supplements, supplements, health functional foods, foods for specified health uses, nutritional functional foods, or foods with functional claims.

11. A method for extracting sugars from red algae, comprising the steps of: A shredding step of crushing the red algae; A drying step of drying the shredded red algae into a plate shape; A soaking step of soaking the red algae dried into a plate shape in a soaking solution; and an extraction step of extracting isofloridoside as the saccharide from the soaking solution. Sugar extraction method.

12. The method for extracting sugars according to claim 11, The red algae is characterized in that it belongs to the genus Neopyropia. Sugar extraction method.

13. The method for extracting sugars according to claim 12, A sorting step of sorting out discolored laver sheets from the dried laver sheets, which are red algae, produced by the drying step; Characterized in that it comprises Sugar extraction method.

14. The method for extracting sugars according to claim 13, The shredding step is characterized in that the red algae is pulverized to a size of 2.5 mm to 5.0 mm. Sugar extraction method.

15. The method for extracting sugars according to claim 13, The extraction step is characterized in that isofloridoside is extracted at an extraction temperature of 1 to 10° C. and / or for an extraction time of 1 to 3 hours. Sugar extraction method.

16. The method for extracting sugars according to claim 13, A purification step of crystallizing the isofloridoside extracted by the extraction step; Characterized in that it comprises Sugar extraction method.

17. The method for extracting sugars according to claim 13, a re-extraction step of extracting Porphyran as the saccharide from the extraction residue obtained in the extraction step; Characterized in that it comprises Sugar extraction method.

18. The method for extracting sugars according to claim 17, a control step of controlling the amount of porphyran extracted in the re-extraction step and the amount of isofloridoside extracted in the extraction step by temperature; Characterized in that it comprises Sugar extraction method.

Citation Information

Patent Citations

  • Method for extracting glycerol galactoside

    JP2007290971A

  • JP2011‐057610A